


TO CURE CANCERS WITH INNOVATION AND SPEED, BY ENABLING THE IMMUNE SYSTEM

Agenus' unique portfolio of novel assets, including best/first-in-class molecules, is designed to deliver optimal combinations to cancer patients. Agenus is driven by industry-leading discovery and manufacturing capabilities and a passionate team – to deliver innovation with speed



Agenus is an innovative biotech with 4 asset categories (Check Point Modulators or CPMs, cell therapy [AgenTus], neoantigen vaccines & adjuvant), designed to deliver optimal combinations of immunotherapy for optimal efficacy for patients with cancer. Our fully integrated capabilities from novel target discovery to GMP manufacturing enable us to deliver innovation with speed! Our discovery engine has outpaced big-pharma in advancing novel discoveries to clinic, with 11 INDs filed in 3 years (2016 - present). We have partnerships with leading pharmas like Gilead, GSK, Incyte & Merck.

OUR PRODUCTS & SERVICES

Our broad portfolio include 4 asset categories:

Immune Checkpoint Antibodies:

- Backbone agents discovered in-house (CTLA-4 and PD-1); BLA path secured for AGEN2034 (PD-1) monotherapy and AGEN1884 (CTLA-4) + AGEN2034 combination (potential BLA filing in 2020). Clinical results show benefit in majority of the >130 patients treated ([presented at AACR, ASCO, ESMO](#))
- Best in class antibodies: NexGen CTLA-4, CD137, TIGIT
- First in class bispecifics designed to address tumor escape mechanisms (intratumor Treg depleting, AGEN1223, or tumor microenvironment conditioning AGEN1423 licensed to Gilead, other undisclosed assets)

Neoantigen Vaccines:

- Individualized AutoSynVax™ (ASV™), which targets unique antigens expressed by a patient's own tumor
- Off-the-shelf (or pre-manufactured PhosphoSynVax™ (PSV™), which targets antigens expressed across patients and tumors, thereby allowing us to treat broader categories of patients
- Vaccine business positioned for combinations

Adjuvant:

- QS-21, part of GSK's Shingrix® vaccine (2018 Revenues >\$1Bn)

Cell Therapy (with our subsidiary AgenTus):

- Novel TCR discovery platform; 2019 INDs on track.

WHAT MAKES US UNIQUE

Our unique portfolio is designed to comprehensively attack cancers from multiple angles such as

- training the immune system to recognize cancers
- boosting an immune response
- blocking cancer escape mechanisms.

This uniquely positions us to pursue novel combinations in the clinic without significant dependence on third parties. In addition, our fully integrated end-to-end capabilities from early discovery to GMP manufacturing, coupled with our proprietary discovery platform, enables us to deliver I-O assets from R&D to clinic, faster than others in the industry.

WHY YOU SHOULD MEET US

Our mission is to bring curative treatment for cancer patients, fast. We have the team, the capabilities, and the pipeline to do so. Our lead programs are advancing towards a potential BLA filing in 2020. Our prolific discovery engine is delivering novel targets in I-O for therapeutic development. To continue these efforts in progressing our pipeline, we are seeking partners who share our vision and goals.

KEY TEAM

Garó Armen, PhD
Chairman & CEO

Jennifer Buell, PhD
Chief Operating Officer

Alex Duncan, PhD
Chief Technology Officer
& Head of Research

Anna Wijatyk, MD
Vice President of
Clinical Development

Christian Cortis, PhD
Chief Strategy Officer &
Head of Finance

Julie DeSander
Vice President, Business
Development and
Alliance Management

SALSS CONTACT
Garó Armen, PhD
Chairman & CEO

armen@agenusbio.com
Office: (212) 994-8201

Agenus Inc
3 Forbes Road
Lexington, MA
02421-7305
USA

www.agenusbio.com

SWEDISH
AMERICAN
LIFE SCIENCE
SUMMIT
2019